686 related articles for article (PubMed ID: 16231324)
21. Integrated first- and second-trimester Down syndrome screening test among unaffected IVF pregnancies.
Maymon R; Shulman A
Prenat Diagn; 2004 Feb; 24(2):125-9. PubMed ID: 14974121
[TBL] [Abstract][Full Text] [Related]
22. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome.
Huang T; Hoffman B; Meschino W; Kingdom J; Okun N
Prenat Diagn; 2010 May; 30(5):471-7. PubMed ID: 20440736
[TBL] [Abstract][Full Text] [Related]
23. Repeated measures screening for Down's Syndrome.
Wright DE; Bradbury I
BJOG; 2005 Jan; 112(1):80-3. PubMed ID: 15663402
[TBL] [Abstract][Full Text] [Related]
24. First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.
Bestwick JP; Huttly WJ; Wald NJ
J Med Screen; 2008; 15(4):204-6. PubMed ID: 19106261
[TBL] [Abstract][Full Text] [Related]
25. Second trimester serum markers.
Canick JA; MacRae AR
Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
[TBL] [Abstract][Full Text] [Related]
26. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
Wald NJ; Watt HC; Hackshaw AK
N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
[TBL] [Abstract][Full Text] [Related]
27. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
28. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K; Bindra R; Cacho AM; Nicolaides KH
Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
[TBL] [Abstract][Full Text] [Related]
29. Integrated serum screening for Down syndrome in primary obstetric practice.
Knight GJ; Palomaki GE; Neveux LM; Smith DE; Kloza EM; Pulkkinen AJ; Williams J; Haddow JE
Prenat Diagn; 2005 Dec; 25(12):1162-7. PubMed ID: 16231402
[TBL] [Abstract][Full Text] [Related]
30. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay.
Talbot JA; Spencer K; Abushoufa RA
Prenat Diagn; 2003 Jan; 23(1):1-5. PubMed ID: 12533803
[TBL] [Abstract][Full Text] [Related]
31. Inhibin A is a maternal serum marker for Down's syndrome early in the first trimester.
Christiansen M; Nørgaard-Pedersen B
Clin Genet; 2005 Jul; 68(1):35-9. PubMed ID: 15952984
[TBL] [Abstract][Full Text] [Related]
32. Practical strategies in contingent sequential screening for Down syndrome.
Benn P; Wright D; Cuckle H
Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
[TBL] [Abstract][Full Text] [Related]
33. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening.
Wright D; Bradbury I; Benn P; Cuckle H; Ritchie K
Prenat Diagn; 2004 Oct; 24(10):762-6. PubMed ID: 15503281
[TBL] [Abstract][Full Text] [Related]
34. First trimester predictors of adverse pregnancy outcomes.
Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
[TBL] [Abstract][Full Text] [Related]
36. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population.
Rozenberg P; Bussières L; Chevret S; Bernard JP; Malagrida L; Cuckle H; Chabry C; Durand-Zaleski I; Bidat L; Lacroix I; Moulis M; Roger M; Jacquemot MC; Bault JP; Boukobza P; Boccara P; Vialard F; Giudicelli Y; Ville Y
Am J Obstet Gynecol; 2006 Nov; 195(5):1379-87. PubMed ID: 16723105
[TBL] [Abstract][Full Text] [Related]
37. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus.
Huttly W; Rudnicka A; Wald NJ
Prenat Diagn; 2004 Oct; 24(10):804-7. PubMed ID: 15503275
[TBL] [Abstract][Full Text] [Related]
38. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome.
Cuckle HS; Holding S; Jones R; Groome NP; Wallace EM
Prenat Diagn; 1996 Dec; 16(12):1095-100. PubMed ID: 8994244
[TBL] [Abstract][Full Text] [Related]
39. Second-trimester maternal serum quadruple test for Down syndrome screening: a Taiwanese population-based study.
Shaw SW; Lin SY; Lin CH; Su YN; Cheng PJ; Lee CN; Chen CP
Taiwan J Obstet Gynecol; 2010 Mar; 49(1):30-4. PubMed ID: 20466289
[TBL] [Abstract][Full Text] [Related]
40. Comparison of first-trimester contingent screening strategies for Down syndrome.
Sahota DS; Leung TY; Chan LW; Law LW; Fung TY; Chen M; Lau TK
Ultrasound Obstet Gynecol; 2010 Mar; 35(3):286-91. PubMed ID: 20052660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
